BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following research. If you own stock and would like to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. You will not incur any costs or financial obligations.
ForgeRock, Inc. (NYSE – FORG)
Under the terms of the agreement, Thoma Bravo will acquire each outstanding share of ForgeRock for $23.25 per share in a cash transaction valued at approximately $2.3 billion. The investigation concerns whether ForgeRock’s board of directors failed in its fiduciary duty to shareholders by failing to conduct a fair trial and whether Thoma Bravo is underpaying the company.
For more information, see https://www.brodskysmith.com/cases/forgerock-inc-nyse-forg/.
SeaSpine Holdings Corporation (Nasdaq-SPNE)
Under the terms of the agreement, SeaSpine will merge with Orthofix (Nasdaq – OFIX). SeaSpine shareholders will receive 0.4163 Orthofix common shares for each SeaSpine common share they own. Upon closing of the transaction, Orthofix shareholders will own approximately 56.5 percent of the combined company and SeaSpine shareholders will own approximately 43.5 percent of the combined company. The investigation concerns whether SeaSpine’s board of directors breached its fiduciary duties to shareholders by failing to conduct due process, including diluting ownership of the combined company.
For more information, see https://www.brodskysmith.com/cases/seaspine-holdings-corporation-nasdaq-spne/.
LogicBio Therapeutics, Inc. (Nasdaq – LOGC)
Under the terms of the merger agreement, LogicBio will be acquired by Alexion, AstraZeneca Rare Disease (“Alexion”). LogicBio shareholders will receive $2.07 in cash for each share of the company they own. The investigation concerns whether LogicBio’s board of directors breached its fiduciary duty to shareholders by…
